The decline has nothing to do with fewer hookups during COVID-19 lockdowns.

Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.

A qualitative study of Black women at risk for HIV in Milwaukee found that low perceived risk and medical mistrust were major barriers.

Experts discuss the topic, and Amida Care recommends solutions. Plus: It’s PrEP Aware Week in the Empire State.

Researchers studied people taking Truvada as PrEP and plan to conduct similar research on newer antiretrovirals.

The Arlington location is one of over 35 clinics in the South operated by CAN Community Health.

None of the people who experienced virologic failure on regimens containing the experimental drug had a viral load of 200 or higher.

Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.

The finding from a 2018 survey raises concerns that men are accessing PrEP without receiving the recommended medical monitoring.

Virtual discussions in Texas and Los Angeles shed light on “the dark side of the rainbow.”